Evaluation of patients on sertindole treatment after failure of other antipsychotics: A retrospective analysis

BMC Psychiatry

Volumn 8, Issue , 2008, Pages

  Azorin, Jean Michel ^a   Murteira, Susana ^b   Hansen, Karina ^b   Toumi, Mondher ^b  

^a HÔPITAL SAINTE MARGUERITE   (France)

^b Lundbeck   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; SERTINDOLE; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE;

ADULT; ARTICLE; AUTOMUTILATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; OBSERVATIONAL STUDY; PSYCHOSIS; RETROSPECTIVE STUDY; SCHIZOPHRENIA; SOCIAL STATUS; SYMPTOM; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; CROSSOVER PROCEDURE; EUROPE; EVALUATION; MIDDLE AGED; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; RETREATMENT; SOCIOECONOMICS; SUICIDE ATTEMPT; TREATMENT FAILURE;

ADULT; ANTIPSYCHOTIC AGENTS; CROSS-OVER STUDIES; EUROPE; FEMALE; HOSPITALIZATION; HUMANS; IMIDAZOLES; INDOLES; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RETREATMENT; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SELF-INJURIOUS BEHAVIOR; SOCIOECONOMIC FACTORS; SUICIDE, ATTEMPTED; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 43049134109     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-8-16     Document Type: Article

References (18)

1. World Health Organization.Regional Office for South-Est Asia Schizophrenia: Youth's Greatest Disabler Word Health Organization. Health & Behavior. Facts and Figures. 2004 http://w3.whosea.org/en/ Section1174/Section1199/Section1567/Section1827.htm
2. Janca A Kastrup M Katschnig H Lopez-Ibor JJ Jr. Mezzich JE Sartorius N The World Health Organization Short Disability Assessment Schedule (WHO DAS-S): A tool for the assessment of difficulties in selected areas of functioning of patients with mental disorders Soc Psychiatry Psychiatr Epidemiol 1996, 31:349-354. 10.1007/BF00783424 8952375
3. Marwaha S Johnson S Schizophrenia and employment - a review Soc Psychiatry Psychiatr Epidemiol 2004, 39:337-349. 10.1007/ s00127-004-0762-4 15133589
4. Gilbert PL Harris MJ McAdams LA Jeste DV Neuroleptic withdrawal in schizophrenic patients. A review of the literature Arch Gen Psychiatry 1995, 52:173-188. 7872841
5. Wyatt RJ Neuroleptics and the Natural Course of Schizophrenia. Schizophr Bull 1991, 17:325-351. 1679255
6. Crow TJ MacMillan JF Johnson AL Johnstone EC A randomised controlled trial of prophylactic neuroleptic treatment Br J Psychiatry 1986, 148:120-127. 2870753
7. Edlinger M Baumgartner S Eltanaihi-Furtmuller N Hummer M Fleischhacker WW Switching between second-generation antipsychotics: Why and how? CNS Drugs 2005, 19:27-42. 10.2165/00023210-200519010-00003 15651903
8. Dossenbach M rango-Davila C Silva IH Landa E Aguilar J Caro O Leadbetter J Assuncao S Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study J Clin Psychiatry 2005, 66:1021-1030. 16086618
9. de Oliveira IR Juruena MF Treatment of psychosis: 30 years of progress J Clin Pharm Ther 2006, 31:523-534. 10.1111/j.1365-2710.2006.00784.x 17176358
10. Leucht S Heres S Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia J Clin Psychiatry 2006, 67(Suppl 5):3-8. 16822090
11. Moore N Hall G Sturkenboom M Mann R Lagnaoui R Begaud B Biases affecting the proportional reporting ratio (PPR) in spontaneous reports pharmacovigilance databases: The example of sertindole Pharmacoepidemiol Drug Saf 2003, 12:271-281. 10.1002/pds.848 12812006
12. The European Agency for the Evaluation of Medicinal Products Sertindole 2002 http://www.emea.europa.eu/pdfs/human/referral/Sertindole/ 285202en.pdf
13. Toumi M Auquier P Francois C The safety and tolerability of sertindole in a named patient program Schizophr Res 2003, 60:368-368. 10.1016/ S0920-9964(03)80203-7
14. Misdrahi D Llorca PM Lancon C Bayle FJ [Compliance in schizophrenia: predictive factors, therapeutical considerations and research implications] Encephale 2002, 28:266-272. 12091789
15. Arnt J Pharmacological differentiation of classical and novel antipsychotics Int Clin Psychopharmacol 1998, 13(Suppl 3):S7-14. 9690964
16. Hyttel J Nielsen JB Nowak G The acute effect of sertindole on brain 5-HT2, D2 and alpha 1 receptors (ex vivo radioreceptor binding studies) J Neural Transm Gen Sect 1992, 89:61-69. 10.1007/BF01245352 1329856
17. Hyttel J Arnt J Costall B Domeney A Dragsted N Lembol HL Meier E Naylor RJ Nowak G Sanchez C. Pharmacological profile of the atypical neuroleptic sertindole Clin Neuropharmacol 1992, 15(Suppl 1, Pt A):267A-268A. 1354033
18. van Kammen DP McEvoy JP Targum SD Kardatzke D Sebree TB A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia Psychopharmacology (Berl) 1996, 124:168-175. 10.1007/ BF02245618 8935813